ArticleTransboundary and emerging diseases2022
First serological evidence of Crimean-Congo haemorrhagic fever virus in transhumant bovines in Italy.
Article in Transboundary and emerging diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Emergence and spread of Hyalomma ticks and Crimean-Congo haemorrhagic fever in Europe: a systematic review.Parasites & vectors · 2025Pooled it
- Spatio-Temporal Dynamics of Crimean Congo Hemorrhagic Fever Virus Infection Using Animal Sentinel Herds in Senegal: March 2021-June 2024.GeoHealth · 2026Article
- Crimean-Congo hemorrhagic fever: An emerging threat in Europe.Virologica Sinica · 2026Review
- Widespread circulation of Crimean-Congo haemorrhagic fever virus in ticks, Corsica (France), 2024.One health (Amsterdam, Netherlands) · 2026Article
- Serological insights of Crimean-Congo haemorrhagic fever virus in podolic cattle bred in Italy.Frontiers in cellular and infection microbiology · 2026Article
- Review
- Evidence of Crimean-Congo hemorrhagic fever virus in livestock and wildlife in Northeastern Portugal.Scientific reports · 2025Article
- Introduction of Vector-Borne Infections in Europe: Emerging and Re-Emerging Viral Pathogens with Potential Impact on One Health.Pathogens (Basel, Switzerland) · 2025Review
- Evaluation of Risk Factors Influencing Tick-Borne Infections in Livestock Through Molecular Analyses.Microorganisms · 2025Article
- Article
- Vectorial dynamics underpinning current and future tick-borne virus emergence in Europe.The Journal of general virology · 2024Review
- Crimean Congo hemorrhagic fever virus nucleoprotein and GP38 subunit vaccine combination prevents morbidity in mice.NPJ vaccines · 2024Article
- Exposure to Crimean-Congo Hemorrhagic Fever Virus in Wild Ungulates in the Basque Country, Northern Iberian Peninsula.Transboundary and emerging diseases · 2024Article
- Epidemic intelligence data of Crimean-Congo haemorrhagic fever, European Region, 2012 to 2022: a new opportunity for risk mapping of neglected diseases.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Article
- First serological evidence of Crimean-Congo haemorrhagic fever virus in transhumant bovines in Italy.Transboundary and emerging diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crimean-Congo haemorrhagic fever (CCHF) is an emerging tick-borne disease caused by the arbovirus Crimean-Congo haemorrhagic fever virus (CCHFV; family Nairoviridae). Given the public health impact, CCHF is considered a priority disease for the European Union. This study describes the first detection of anti-CCHFV antibodies in transhumant bovines in Italy. Sera from 794 cattle collected across Basilicata region (Southern Italy) were screened using a commercial ELISA kit. The animal-level and herd-level seroprevalences detected were 1.89% [95%CI: 1.12-3.1] and 29.63% [95%CI: 15.68-48.65], respectively. Results of the χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.